1. Scrip

Tymlos Inclusion Stands Out As Express Scripts Reveals 2018 Formulary

 
• By Mandy Jackson

Radius Health's pricing and reimbursement strategy has been successful, at least with Express Scripts, which included its bone-builder Tymlos on a 2018 formulary that excludes several brand-name drugs.

Syringes stuck in a dartboard

Express Scripts Holding Co. cut 64 additional drugs from its formulary for 2018, making brand-name medicines included on the pharmacy benefit manager's (PBM's) list of covered therapies – like Radius Health Inc.'s new osteoporosis drug Tymlos (abaloparatide) – notable exceptions to the PBM's new rules.

The bone-building drug was included on the Express Scripts formulary to the detriment of a competing, well-established and more costly anabolic agent – Eli Lilly & Co.'s Forteo (teriparatide), which was excluded

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.